|
Media Releases |
Financial Reports |
Presen-tations |
|
08/30/2007
|
|
|
|
| The Exclusive Synthesis small scale plant will come on stream in September 2007. |
Basel, August 30, 2007 – In April of 2006, Lonza unveiled a significant investment plan to substantially develop its Nansha Guangzhou, China operations towards the construction of an integrated Exclusive Synthesis platform with R&D capabilities as well as small and large scale cGMP manufacturing. After the R&D Group has been very successfully operating since the end of 2005 with overwhelming support from our global customers, the small scale plant will come on stream in September 2007 as the next step.
This world class facility, which operates under cGMP conditions, is designed to accommodate a greater number of reactors including a dedicated and technologically advanced Quality Control lab capable to fulfill the ever increasing requirements of global regulatory authorities on the highest possible level. In the completed first build-out phase, six smaller reactors including distillation and filtration units are installed, capable of handling a broad range of technologies. The configuration ensures fast change over, optimized efficiencies and extremely rapid technical transfer to commercial assets. Additional capacity can be added without impacting running operations.
The plant is designed for production of quantities from 10 kilograms up to several hundreds of kilograms, and closes the gap between Nansha’s kilo lab and commercial production assets to allow complete life-cycle support for pharmaceutical products out of China. The commercial scale API facility in Nansha is currently under construction and will house up to 200m3 reactor volume.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006, Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.
For further information:
Media Relations Lonza
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 97 98
dominik.werner@lonza.com
Investor Relations Lonza
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835
alexandre.pasini@lonza.com
|
|
|
